Company intelligence / Profile preview

上海昂昇生物医药科技

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

OnSheng Biomedical is a Shanghai-based biotechnology company specializing in the discovery and development of next-generation targeted protein degradation (TPD) therapies. The company leverages its proprietary platform to design molecular glues and PROTACs aimed at previously "undruggable" targets in oncology and immunology. OnSheng's pipeline includes several small molecule candidates currently in the pre-clinical and IND-enabling stages. By focusing on high-efficiency degradation mechanisms, the company seeks to provide transformative treatments for patients with refractory cancers and complex autoimmune conditions.

Therapeutic areas: ImmunologyOncology
Modalities: Small moleculeProteolysis-targeting chimera therapyMolecular glue therapy
Industry: Biotech

Beyond the preview

Go deeper on 上海昂昇生物医药科技.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 上海昂昇生物医药科技.

Explore the full profile